Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

13.05.2024

1 Abdom Radiol (NY)
2 Actas Urol Esp (Engl Ed)
1 Altern Ther Health Med
2 Ann Pathol
1 Ann Surg Oncol
1 Arch Esp Urol
1 Arch Ital Urol Androl
1 Asian J Surg
1 Biochem Genet
1 Biomol Biomed
2 BJU Int
1 Cell Mol Biol Lett
1 Clin Chim Acta
1 Discov Oncol
1 Eur Urol Oncol
1 Front Public Health
1 Future Oncol
1 Genet Res (Camb)
1 Heliyon
1 Hum Pathol
1 Indian J Urol
1 Int J Immunopathol Pharmacol
1 Int J Qual Health Care
2 Int J Surg
5 Int J Urol
5 Investig Clin Urol
1 J Cancer
1 J Family Reprod Health
1 J Pathol
1 J Surg Res
2 J Urol
1 Mol Oncol
1 Nanoscale
1 Pathol Res Pract
1 PLoS One
1 Proc Natl Acad Sci U S A
2 Sci Rep
2 Transl Androl Urol
1 Tumori
1 Urol J
1 Urol Oncol
1 Urologie
2 Vet Comp Oncol
1 World J Urol



    Abdom Radiol (NY)

  1. KHWAJA SA, Caglic I, Shaida N, Colquhoun AJ, et al
    Evaluation of magnetic resonance imaging for bladder cancer detection following transurethral resection of bladder tumour (TURBT).
    Abdom Radiol (NY). 2024 May 8. doi: 10.1007/s00261-024-04235.
    >> Share


    Actas Urol Esp (Engl Ed)

  2. WANG Z, Bi H, Wang YD, Liu Q, et al
    Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
    Actas Urol Esp (Engl Ed). 2024;48:295-303.
    >> Share

  3. GUERRERO-RAMOS F, Alvarez-Maestro M, Pinto Marin A, Dominguez Escrig JL, et al
    Multidisciplinary consensus document on the current treatment of bacille Calmette-Guerin-unresponsive non-muscle invasive bladder tumor.
    Actas Urol Esp (Engl Ed). 2024;48:262-272.
    >> Share


    Altern Ther Health Med

  4. ISAACS LL, Gonzalez NJ
    The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer.
    Altern Ther Health Med. 2024 May 3:AT9333.
    >> Share


    Ann Pathol

  5. BAJEOT AS, Roumiguie M
    [Not Available].
    Ann Pathol. 2024;44:183-187.
    >> Share

  6. LACOSTE-COLLIN L
    [What contribution can make artificial intelligence to urinary cytology?].
    Ann Pathol. 2024;44:195-203.
    >> Share


    Ann Surg Oncol

  7. SONG W, Yu J, Jeong BC
    ASO Author Reflections: Advancing Early Outcome Assessment in Robot-Assisted Radical Cystectomy: RARC Tetrafecta.
    Ann Surg Oncol. 2024;31:3908-3909.
    >> Share


    Arch Esp Urol

  8. HU H
    Effectiveness and Safety of Extended Lymph Node Dissection during Radical Surgery in Patients with Bladder Cancer: A Meta-Analysis.
    Arch Esp Urol. 2024;77:303-314.
    >> Share


    Arch Ital Urol Androl

  9. MACDONALD A, Bao L, Mehrnoush V, Ismail A, et al
    Does intravesical BCG for bladder cancer protect from COVID-19?
    Arch Ital Urol Androl. 2024 May 9:12449. doi: 10.4081/aiua.2024.12449.
    >> Share


    Asian J Surg

  10. WANG XJ, Qiu X
    A case of primary small-cell neuroendocrine carcinoma of the bladder.
    Asian J Surg. 2024;47:2421-2422.
    >> Share


    Biochem Genet

  11. VALIZADEH S, Taghiyar S, Vahidi S, Abazari O, et al
    Application of PLK1 and HOXA13 Gene Expression Levels in Urine in the Diagnosis of Non-muscle Invasive Bladder Cancer.
    Biochem Genet. 2024 May 7. doi: 10.1007/s10528-024-10735.
    >> Share


    Biomol Biomed

  12. LI Z, Xu Z, Wang J, Wang M, et al
    Nomograms for predicting the overall and cancer-specific survival in patients with non-urothelial carcinoma of the bladder: A population-based study.
    Biomol Biomed. 2024;24:633-646.
    >> Share


    BJU Int

  13. HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
    Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
    BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
    >> Share

  14. PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
    How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
    BJU Int. 2024;133:673-677.
    >> Share


    Cell Mol Biol Lett

  15. ZHAN T, Li X, Liu J, Ye C, et al
    CRISPR-based gene expression platform for precise regulation of bladder cancer.
    Cell Mol Biol Lett. 2024;29:66.
    >> Share


    Clin Chim Acta

  16. CHENG K, Wan S, Chen SY, Yang JW, et al
    Nuclear matrix protein 22 in bladder cancer.
    Clin Chim Acta. 2024 May 6:119718. doi: 10.1016/j.cca.2024.119718.
    >> Share


    Discov Oncol

  17. YIN T, Mou S, Zhang H, Dong Y, et al
    CXCL10 could be a prognostic and immunological biomarker in bladder cancer.
    Discov Oncol. 2024;15:148.
    >> Share


    Eur Urol Oncol

  18. BUKAVINA L, Helstrom E, Wallis CJD, Fulmes A, et al
    Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers.
    Eur Urol Oncol. 2024 May 2:S2588-9311(24)00098-1. doi: 10.1016/j.euo.2024.
    >> Share


    Front Public Health

  19. FENG L, Huang G, Peng L, Liang R, et al
    Comparison of bladder carcinogenesis biomarkers in the urine of traditional cigarette users and e-cigarette users.
    Front Public Health. 2024;12:1385628.
    >> Share


    Future Oncol

  20. LI J, Li H, Yang Y, Sen Y, et al
    miRNA-143 as a potential biomarker in the detection of bladder cancer: a meta-analysis.
    Future Oncol. 2024 May 9. doi: 10.2217/fon-2023-0922.
    >> Share


    Genet Res (Camb)

  21. ZHOU Y, Zheng X, Sun Z, Wang B, et al
    Analysis of Bladder Cancer Staging Prediction Using Deep Residual Neural Network, Radiomics, and RNA-Seq from High-Definition CT Images.
    Genet Res (Camb). 2024;2024:4285171.
    >> Share


    Heliyon

  22. YAO Z, Yang L, Yang X, Liu F, et al
    Stimulator of interferon genes mediated immune senescence reveals the immune microenvironment and prognostic characteristics of bladder cancer.
    Heliyon. 2024;10:e28803.
    >> Share


    Hum Pathol

  23. IRWIN T, Donlan AW, Owens L, Alvarez R, et al
    Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Hum Pathol. 2024;146:43-48.
    >> Share


    Indian J Urol

  24. SHARMA AP, Singh PP, Chauhan R, Panda I, et al
    Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting.
    Indian J Urol. 2024;40:127-132.
    >> Share


    Int J Immunopathol Pharmacol

  25. LIN YZ, Liu WH, Wu YP, Cai H, et al
    Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications.
    Int J Immunopathol Pharmacol. 2024;38:3946320241240706.
    >> Share


    Int J Qual Health Care

  26. PLOUVIER SD, Marcq G, Vankemmel O, Colin P, et al
    Practice patterns and survival outcomes for Muscle-Invasive Bladder Cancer: real-life experience in a general population setting.
    Int J Qual Health Care. 2024 May 6:mzae040. doi: 10.1093.
    >> Share


    Int J Surg

  27. ZHENG Y, Shi H, Hai B, Zhang J, et al
    A commentary on "A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study".
    Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001510.
    >> Share

  28. LIU Y, Zhang X, Shang P
    Comment on 'HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study'.
    Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001527.
    >> Share


    Int J Urol

  29. ISHIHARA H, Takagi T
    Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:559-560.
    >> Share

  30. KONDO T
    Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:560-561.
    >> Share

  31. MIYAKE M
    Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
    Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
    >> Share

  32. KITA Y, Otsuka H, Ito K, Hara T, et al
    Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:552-559.
    >> Share

  33. TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
    Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
    Int J Urol. 2024;31:512-518.
    >> Share


    Investig Clin Urol

  34. PAK S, Park SG, Park J, Cho ST, et al
    Applications of artificial intelligence in urologic oncology.
    Investig Clin Urol. 2024;65:202-216.
    >> Share

  35. CHOI J, Kim KH, Kim HS, Yoon HS, et al
    Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guerin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective m
    Investig Clin Urol. 2024;65:248-255.
    >> Share

  36. KANG H, Suh J, You D, Jeong IG, et al
    Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.
    Investig Clin Urol. 2024;65:256-262.
    >> Share

  37. QIN R, Ma X, Pu S, Shen C, et al
    Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.
    Investig Clin Urol. 2024;65:263-278.
    >> Share

  38. KIM DH, Choi MS, Choi JH, Lee C, et al
    Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence.
    Investig Clin Urol. 2024;65:279-285.
    >> Share


    J Cancer

  39. YANG J, Liu X, Dai G, Qu L, et al
    Erratum: CircNT5E promotes the proliferation and migration of bladder cancer via sponging miR-502-5p: Erratum.
    J Cancer. 2024;15:3152-3153.
    >> Share


    J Family Reprod Health

  40. GHORBANI H, AfzalAghai M, Soltani S, Mottaghi M, et al
    Translation, Linguistic Validation, and Cultural Adaptation of the Bladder Cancer Index (BCI) Questionnaire Into the Persian (Farsi) Language and Comparing it With WHO Quality of Life Questionnaire: An Observational Study.
    J Family Reprod Health. 2023;17:128-135.
    >> Share


    J Pathol

  41. JIN K, Xu J, Su X, Xu Z, et al
    TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
    J Pathol. 2024;263:139-149.
    >> Share


    J Surg Res

  42. SUGUMAR K, De Mond J, Vijay A, Paramesh AS, et al
    Bile Spillage as a Prognostic Factor for Gall Bladder Cancer: A Systematic Review and Meta-analysis.
    J Surg Res. 2024;299:94-102.
    >> Share


    J Urol

  43. NARAYAN VM, Boorjian SA, Alemozaffar M, Konety BR, et al
    Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
    J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020.
    >> Share

  44. DJALADAT H, Ghoreifi A, Tejura T, Miranda G, et al
    Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
    J Urol. 2024;211:743-753.
    >> Share


    Mol Oncol

  45. VEDELD HM, Pharo H, Sorbo AK, Brandt-Winge S, et al
    Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.
    Mol Oncol. 2024 May 8. doi: 10.1002/1878-0261.13639.
    >> Share


    Nanoscale

  46. CHEN W, Wang Y, Hu H, Zhu Y, et al
    NIR-II light powered hydrogel nanomotor for intravesical instillation with enhanced bladder cancer therapy.
    Nanoscale. 2024 May 8. doi: 10.1039/d4nr01128.
    >> Share


    Pathol Res Pract

  47. CAI Z, Cheng X, Liao S, Zou W, et al
    POU2F3-positive small cell carcinoma of the bladder: A clinicopathologic analysis of 4 cases and literature review.
    Pathol Res Pract. 2024;257:155296.
    >> Share


    PLoS One

  48. PORTE F, Granghaud A, Chang J, Kearney M, et al
    Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
    PLoS One. 2024;19:e0302548.
    >> Share


    Proc Natl Acad Sci U S A

  49. JING W, Wang G, Cui Z, Li X, et al
    Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression.
    Proc Natl Acad Sci U S A. 2024;121:e2312855121.
    >> Share


    Sci Rep

  50. CHENG G, Zhou Z, Li S, Yang S, et al
    Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes.
    Sci Rep. 2024;14:10482.
    >> Share

  51. CHOI J, Lee J, Hwang YB, Jeong BC, et al
    Preoperative smoking and robot-assisted radical cystectomy outcomes & complications in multicenter KORARC database.
    Sci Rep. 2024;14:10550.
    >> Share


    Transl Androl Urol

  52. GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
    Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?
    Transl Androl Urol. 2024;13:639-642.
    >> Share

  53. LICHTBROUN B, Ghodoussipour S, Packiam VT
    Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?
    Transl Androl Urol. 2024;13:647-649.
    >> Share


    Tumori

  54. MARVASO G, Vitullo A, Corrao G, Vincini MG, et al
    Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?
    Tumori. 2024 May 10:3008916241252326. doi: 10.1177/03008916241252326.
    >> Share


    Urol J

  55. CANAKCI C, Ozkaptan O, Dincer E, Ipek OM, et al
    Perioperative Outcomes of Open Extra-peritoneal Versus Laparoscopic Radical Cystoprostatectomy: A single Center Comparative Study.
    Urol J. 2024;21:175-181.
    >> Share


    Urol Oncol

  56. MELCHIODE Z, Hu S, Xu J, Riveros C, et al
    Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy database.
    Urol Oncol. 2024 May 2:S1078-1439(24)00404-6. doi: 10.1016/j.urolonc.2024.
    >> Share


    Urologie

  57. ECKE TH, Wirtz RM, Heidenreich A, Fussel S, et al
    [Multicenter networks, innovative concepts, and basic research-the mixture is important: report from the 14th symposium of the German Research Group on Bladder Cancer (DFBK) in Cologne].
    Urologie. 2024 May 6. doi: 10.1007/s00120-024-02353.
    >> Share


    Vet Comp Oncol

  58. BRAMAN SL, Peterson H, Elbe A, Mani E, et al
    Urinary and household chemical exposures in pet dogs with urothelial cell carcinoma.
    Vet Comp Oncol. 2024;22:217-229.
    >> Share

  59. AESCHLIMANN L, Kehl A, Guscetti F, Posthaus C, et al
    Effective detection of BRAF(V595E) mutation in canine urothelial and prostate carcinomas using immunohistochemistry.
    Vet Comp Oncol. 2024;22:295-302.
    >> Share


    World J Urol

  60. SHINDO T, Hashimoto K, Fujino K, Takahashi A, et al
    Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
    World J Urol. 2024;42:307.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016